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Prostate cancer is the most common cancer among males in the United States and there is 
lack of consensus as to whether active surveillance (AS) or radical prostatectomy (RP) is the 
best course of treatment. In this study we examined the role of three overlooked determinants 
of decision making about prostate cancer treatment in a hypothetical experiment—numeracy, 
time discounting, and risk taking in 279 men over age 50 without a prior prostate cancer 
diagnosis. Results showed that AS was the most frequently chosen option. Furthermore, 
numeracy and time discounting significantly predicted participants’ preference for AS, 
whereas a propensity to take risks was associated with a preference for RP. Such insights into 
the factors that affects cancer treatment preferences may improve tailored decision aids and 
help physicians be better poised to engage in shared decision-making to improve both 
patient-reported and clinical outcomes.   










Prostate cancer is the most common cancer among U.S. men (Centers for Disease 
Control and Prevention, 2014), with an estimated 233,000 diagnosed cases and 30,000 deaths 
in 2014 (National Cancer Institute, 2014). There is little agreement among oncologists about 
the best course of treatment (Moyer & U.S. Preventive Services Task Force, 2012). Indeed, 
for the majority of men who have low-risk stage 1 (also called localized) prostate cancer, the 
two most common options—active surveillance (AS) and radical prostatectomy (RP)—have 
equivalent survival rates over a period of 12 years (Wilt et al., 2012). Yet, the two treatments 
have drastically different trade-offs (Bill-Axelson et al., 2011). Men with localized prostate 
cancer are faced, therefore, with the difficult question of which treatment to pursue.  
Both approaches have potential benefits and risks that could influence a man’s 
decision about which course of treatment to pursue and, consequently, his quality of life 
(Catalona et al., 2012). AS may involve more prostate biopsies, which can have short-term 
side effects such as transitory urinary incontinency (Moyer & U.S. Preventive Services Task 
Force, 2012). Furthermore, as AS does not involve the elimination of the tumour, it may 
carry the risk that it may grow more quickly than expected and become more difficult to treat 
later (Wilt et al., 2012). These two concerns can increase anxiety among men about their 
cancer status changing (Catalona et al., 2012). RP, on the other hand, reduces the possibility 
of future cancer growth but has notable shortcomings: About 20% of patients who undergo 
RP suffer from urinary incontinence (Wilt et al., 2012), and close to 60% suffer from erectile 
dysfunction (Boorjian et al., 2011).  
Given the complexity of the treatment choices, the American Cancer Society 
recommends men should engage in a shared decision-making process (Aning, Wassersug, & 
Goldenberg, 2012) in which clinicians and patients share the best available evidence, and 
patients are encouraged to consider their options and arrive at their own informed preferences 




(Elwyn et al., 2012). Research on prostate cancer treatment decisions has revealed that 
patients have misconceptions about the benefits and risks of the options they face (Beydoun 
et al., 2010). Prior evidence suggests that 98% of patients who chose the surgery option 
thought it was a guaranteed cure (Hall, Boyd, Lippert, & Theodorescu, 2003). Further, men 
with a higher likelihood of prostate cancer frequently misperceive their own risk, even when 
provided with tailored decision aids (Watts et al., 2014).  
Factors that may affect patients’ decision making 
One vital question is what patient-level psychological factors contribute to the 
variation in treatment choices. Being able to make a treatment decision, such as whether to 
choose AS or RP, may be affected by patient’s level of anxiety, his marital status, the 
influence of his urologist, or the use of internet to gather information about the illness or risk 
and benefits of the treatments (e.g., Berry et al., 2006).  Additionally, one of potentially 
important predictor of prostate cancer treatment choice is numeracy, which refers to a 
person’s ability to process and understand numerical information (Rudd, Colton, & Schacht, 
2000). Numeracy has the potential to affect a variety of important outcomes ranging from 
health decision making to adherence to therapy (Reyna et al., 2009). Much of the research on 
the relationship between numeracy and medical decision making has been conducted with 
breast cancer patients, where it has been shown that less numerate women have more 
difficulties correctly interpreting survival and risk information (Dillard, McCaul, Kelso, & 
Klein, 2006); they tend to express greater confusion about treatment results (Lipkus, Peters, 
Kimmick, Liotcheva, & Marcom, 2010); and they are more likely to overestimate the benefit 
of screening (Schwartz, Woloshin, Black, & Welch, 1997). Of particular importance to trade-
offs between AS and PR, numeracy relates to the ability to assess risk magnitude, compare 
risks, and understand probabilities—information that plays a part in the decision-making 
process (Burkell, 2004). In fact, Reyna, Nelson, Han, and Dieckmann (2009) argued that 




numeracy is crucial in those medical contexts where the decision-making process is shared 
between the practitioner and the patient, as may be the case for localized prostate cancer 
treatment.  
In addition to numeracy, time discounting is another crucial determinant of treatment 
choices and, therefore, it may also play a pivotal role in localized prostate cancer treatment 
decisions. Time discounting  refers to decisions involving  trade-offs among costs and 
benefits at now versus later (Frederick, Loewestein, & O’Donoghue, 2002, p. 351). In the 
context of health, time discounting refers to preference for smaller, more immediate vs. 
larger, more distant health benefits (Frederick, Loewenstein, & O’Donoghue, 2002; Khwaja, 
Silverman, & Sloan, 2007;Frederick et al., 2002). Higher discount rates have been linked to 
impulsive decision making (Wittmann & Paulus, 2008), which may lead to an overestimation 
of both risks and benefits in the decision-making process (Zimmermann, 2010). Earlier 
examinations of time discounting have mainly focused on risky health behaviours (Bradford, 
2010). For instance, investigations focusing on smoking suggested that people with higher 
discount rates are more likely to smoke (Mitchell, 1999).  A study using the Health and 
Retirement Survey data from the United States has shown that those who exhibit higher 
discounting rates are also less likely to undergo mammography or prostate cancer screening 
(Bradford, 2009). Given that patients who are considering AS and RP have to evaluate the 
time trade-off between the two options (i.e., RP offers an immediate treatment and, 
potentially, more immediate consequences, whereas AS relies on delay taking action), we 
expected that time discounting may play a role in patients’ decision to opt for AS or undergo 
RP.   
Differences in the decision-making processes that involve risk and uncertainty may 
also emerge from individual differences in risk attitude (Blais & Weber, 2006). Tendencies to 
engage in a risky behaviour or treatments—for example, smoking or undergoing knee 




replacement surgery to treat arthritis—depend on a person’s willingness to bear the risk of an 
uncertain or potentially harmful outcome (Butler et al., 2012). As such, willingness to pursue 
one localized prostate cancer treatment option over another might depend on a patient’s risk 
attitude towards the potential health and quality of life benefits and consequences each 
decision confers. Despite the potential importance of numeracy, time discounting and risk 
attitudes evaluating trade-offs (Blais & Weber, 2006; Reyna et al., 2009; Zimmerman, 2010), 
there is a lack of data on how these factors relate to localized prostate cancer treatment 
decisions. 
The Present Research 
 This study was designed to examine whether numeracy, time discounting and risk 
attitudes might help distinguish between men who opt for AS and men who decide to 
undergo RP in a hypothetical experiment. The use of similar hypothetical scenarios is a 
methodology that has been used successfully in previous literature on medical decision 
making (e.g., Fagerlin, Zikmun-Fisher, & Ubel, 2005; Gavaruzzi, Lotto, Rumiati, & Fagerlin, 
2011).  We hypothesized that high-numeracy individuals would choose AS more often as 
their preferred treatment option. We believe that higher numeracy individuals would choose 
AS for two main reasons. First, higher numeracy is associated with better comprehension of 
lifetime risk of developing prostate cancer (Rolison, Hanoch, & Miron-Shatz, 2012). 
Secondly, it has been shown (Peters, Västfjäll, Slovic, Mertz, Mazzocco, & Dickert, 2006) 
that low numeracy individuals are more likely to be swayed by affective factors, in our case 
knowledge that they have cancer. Our second hypothesis was that  high discount rates would 
prefer to delay treatment choices and would be more likely to choose AS as their preferred 
treatment option. In this regard, we expected that people high in time discounting would 
place more decision weight on avoiding RP as it offers more immediate consequences (i.e., 
surgery, erectile dysfunction) and more distant benefits (i.e., cancer survival), whereas AS 




relies on more immediate benefits (i.e., avoiding surgery) and more distant consequences 
(i.e., potential for the cancer to spread). Finally, as the mortality risks of AS and RP are 
equivalent but morbidity risks vary substantially,  we remained agnostic about the 




 Participants (n=277) who were male, age 50 and older, and without a prostate cancer 
diagnosis were recruited from Amazon Mechanical Turk (https://requester.mturk.com/) and 
received a token payment of 0.25 U.S. dollars. The reliability of the Amazon Mechanical 
Turk participant sample has been validated elsewhere by comparisons with other samples and 
recruitment methods (Mason & Suri, 2012).  
Materials 
Treatment option. To examine treatment preference, participants read a short scenario 
that provided them with general information about prostate cancer, such as its prevalence in 
the population, mortality rates, and that there is no one treatment option for low-risk 
(localized) prostate cancer (see Appendix 1). They were then provided with more in-depth 
information about two treatment options: AS and RP. The information about each treatment 
option included data on the possible risks and benefits. Next, they were told that recent 
studies have found similar mortality rate for the two treatment options. After reading the 
scenario, participants were asked to imagine that they had been diagnosed with prostate 
cancer and to indicate which of the two treatment options they would prefer. To mitigate 
recency and primacy effects, the presentation of the information was counterbalanced, such 
that half of the participants read about AS first and half of the participants read about RP first. 




Information about prostate cancer and treatment options was taken from the National Cancer 
Institute website.  
Numeracy. Respondents completed four items from a validated objective numeracy 
measure (Lipkus, Samsa, & Rimer, 2001), which examines individuals’ capacity to solve 
basic probability and ratio problems. These numeracy questions have been used in multiple 
studies, across diverse populations, and in multiple medical-decision-making domains. Its 
psychometric properties are well established. Questions were scored as either correct (coded 
“1”) or incorrect (coded “0”). We combined the scores for the four questions and treated the 
overall numeracy scores as a continuous variable (range from 0 to 4). 
Time discounting. To evaluate time discounting, participants were asked four 
questions about preferences for winning and losing various amounts of money now vs. year 
from now (i.e., win $20 vs. $30, lose $20 vs. $30, win $1,000 vs. $1,500, lose $1,000 vs. 
$1,500). The questions were taken from a study by Khwaja et al. (2007) where this measure 
was validated in predicting risky health behaviors. The time discounting measure was 
constructed by summing the responses where individuals preferred smaller, more immediate 
winnings and larger, more distant losses across the four questions. Individuals who reported 
they would rather win less money now and lose more money later were considered to have 
higher discount rates and thus higher scores on this 0–4 scale.  
Risk attitudes.  Participants also responded to items from the Domain-Specific Risk-
Taking Scale (DOSPERT; Blais & Weber, 2006) to assess their risk attitudes. The survey 
included only three of the DOSPERT’s five domains (i.e., health, investment, and gambling). 
We only included the three domains that previous literature linked with medical decision-
making (e.g., Rosman, Garcia, Lee, Butler & Schwartz, 2013).  For each item in a domain, 
participants indicated their likelihood of engaging in the risky activity (e.g., riding a bicycle 
without a helmet in the health domain, betting a day’s income in the gambling domain, 




investing 10% of their income in a speculative stock in the investment domain). All responses 
were on a 7-point Likert scale ranging from 1 (extremely unlikely) to 7 (extremely likely), 
where higher values indicated greater risk taking. Responses were averaged across questions 
in each of the three domains. 
Procedure 
First, participants completed a simple demographic questionnaire. They then read the 
information about prostate cancer and the benefits and risks associated with AS and RP. 
Next, participants were asked to imagine that they had been diagnosed with prostate cancer 
and were asked to choose either AS or RP as a treatment. Finally, participants were asked if 
they had been tested for prostate cancer as well as the numeracy, time discounting, and risk 
attitude assessments.  
Statistical Approach 
 Univariate statistics were used to describe the sample.  Bivariate associations between 
choosing AS vs. RP and demographics were assessed using Chi-square tests.  Adjusted 
associations of treatment choices were examined using logistic regression, where 1 indicated 
choosing RP and 0 indicated choosing AS.  
Results 
Sample Characteristics 
By design, all participants were male. Most participants chose AS (80%) over RP 
(20%) (Table 1). Concerning education, 11% had finished high school, 27% had obtained an 
associate’s degree, 48% a bachelor’s degree, and 14% a master’s or doctorate degree. 
Regarding race and ethnicity, 80% were Caucasian, 8% were Latin-American and 12% were 
African-American. Participants ranged in age from 50–76 years (mean 56.22; SD = 5.46). 
Forty-nine percent of participants reported having undergone prostate cancer screening in the 
past.  




[INSERT TABLE 1 HERE] 
Associations of Treatment Choice, Education, and Prior Screening 
Next, we tested whether education level influenced the choice of treatment. The 
results showed that there were no differences in treatment choice among the different 
education levels, χ2(6) = 6.68, p =.36. Having been screened for prostate cancer was also 
found to have no effect, such that participants who had been tested (79% who chose AS vs. 
21% who chose RP) and those who had not (82% who chose AS vs. 18% who chose RP) 
made similar treatment decisions, χ2(1) = .57, p =.55.  
Associations of Treatment Choice, Numeracy, Time Discounting, and Risk Attitudes 
As there were no unadjusted differences in the treatment choice and demographics, 
these variables were not included in the regression analysis. Thus, the adjusted logistic 
regression model presented below included only numeracy, time discounting, and the three 
risk domains of the DOSPERT.  
[INSERT TABLE 2 HERE] 
Our adjusted results found that more numerate individuals were less likely to choose 
RP over AS compared to those with low numeracy skills (Table 2). Each one-point increase 
on the numeracy scale was associated with 0.663 times the odds of choosing RP (p < .05). 
Time discounting was also negatively associated with the odds of choosing RP over AS such 
that each one-point increase in preference for smaller, more immediate gains and larger, less 
immediate losses was associated with 0.683 times the odds of choosing RP (p < .05). 
Conversely, the propensity to engage in risky gambling behaviours was positively associated 
with the odds of choosing RP in that each one-point increase in risk taking in the gambling 
domain was associated with 1.103 times the odds of choosing RP (p < .05).  
 
Discussion 




More men are being diagnosed with localized prostate cancer and the American 
Urological Association (Thompson et al., 2007) has recommended that these patients be 
informed about the treatment options available to them. Men diagnosed with localized 
prostate cancer are thus faced with a very difficult dilemma: which option to pursue. 
Although some earlier studies explored patients’ reasons for choosing one option over the 
other (e.g., Anandadas et al., 2010; Bekker-Grob et al., 2013), there is a paucity of empirical 
data on the psychological variables that may explain these decisions (Watts et al., 2014).   
 Results from our study showed that numeracy was one of the main predictors of 
participants’ treatment choices. In line with our hypothesis, high-numeracy individuals were 
significantly more likely to opt for AS than RP. This may be due to the way highly numerate 
individuals interpret the risk and benefits associated with each option. Our data, thus, provide 
further support to a growing corpus of evidence highlighting the vital role numeracy plays in 
a wide range of health and medical decision-making. Indeed, while earlier investigations 
focused on the link between numeracy and understanding risk information and screening 
decisions, especially concerning breast cancer, our findings, along with Lipkus et al.’s (2001) 
work, show that numeracy plays an important role in prostate cancer treatment decisions. 
Although we did not find an effect of education, it is possible  the high level of education in 
our sample attenuates these effects.  Future research should investigate the link between 
numeracy, education, and treatment choices further.   
Concerning time discounting, our results demonstrated the predicted trend: 
individuals with higher discount rates were more likely to choose AS. Given that one of the 
key features of RP is the uncertain mortality benefit and the high-probability risks of the 
surgery (i.e., incontinence and impotence), it is likely than those who are more present 
oriented would want to avoid such risks unless it is necessary to reduce mortality (Frederick 




et al, 2002). Similarly, earlier studies investigating prostate cancer screening found that 
higher time discounting was associated with lower screening likelihood (Bradford, 2009).  
Finally, we found evidence that risk taking in the gambling domain, but not in the 
investment or health domain, was associated with a preference for RP. Prosser and 
Wittenberg (2007) had similar findings reporting that individuals tend to be risk neutral in the 
health domain. In contrast, however, Prosser, Kuntz, Bar-Or, and Weinstein (2002), reported 
that risk attitude was associated with treatment choice for patients with multiple sclerosis, 
such that more-risk-seeking individuals were less likely to choose to be treated. However, the 
two treatment options for prostate cancer differ substantially from those for multiple 
sclerosis.  In our study, the treatments presented to our participants have similar mortality risk 
but present different morbidity risks.  
 The present study has several notable limitations. First, our sample was one of 
convenience and it is difficult to make valid generalizations to the treatment decisions of 
clinical population at risk for prostate cancer. For instance, our data revealed that the majority 
(80%) of participants would opt for active surveillance. Conversely, a study by Anandadas et 
al. (2010) with prostate cancer patients found that only 8% chose AS as their preferred 
option, and Cooperberg et al. (2007) found that RP seemed to be the most preferred option. 
Supporting our findings, however, Bekker-Grob et al. (2013) found that a similar percentage 
of men would choose AS. In fact, 77% of the urologists in their study and 76% of patients 
without anxious/depressed feelings chose AS as their preferred option. Furthermore, a U.S. 
National Institutes of Health Consensus and State-of the-Science panel argued that AS should 
be offered to men with low-risk prostate cancer (Penson, 2012). It is possible, thus, that the 
rate of men opting for AS might increase. 
Second, our study was hypothetical in nature; however, participants did not differ in 
their hypothetical treatment choice and actual screening history. Future studies should 




examine the role of numeracy, time discounting, and risk taking in the clinical setting prior to 
screening and after diagnosis to establish their relationship to actual treatment decision. We 
did not, furthermore, present participants with the entire spectrum of treatment options 
currently available. One rationale for this restriction rests on the fact the Wilt et al.’s (2012) 
work focused on comparing survival rates of only two options. Indeed, deciding which option 
to pursue is a far more complex process and involves more information than we could present 
in this study. Despite these limitations, our study allowed us to examine, for the first time to 
our knowledge, the role of numeracy, risk taking, and time discounting in men’s decisions 
about prostate cancer treatment.  
 Our results also provide important insights about the factors that might affect men’s 
treatment preferences. We found some evidence of an influence of discount rates and 
gambling risk attitudes in treatment decisions but more studies are needed before determining 
whether clinicians should address these patient-level factors. However, our findings could 
have important implications for the design of decision aids and the information included 
when communicating options in the clinical setting. Indeed a number of studies have shown 
that prostate cancer patients do not receive the necessary information to make an informed 
decision (e.g., Steginga, Occhipinti, Gardiner, Yaxley, & Heathcote, 2002). Yet there is 
growing evidence that decision aids can help patients adopt an active role in the decision-
making process, decrease their anxiety levels, and reduce their sense of uncertainty (Lin, 
Aaronson, Knight, Carroll, & Dudley, 2009). Addressing numeracy levels in prostate cancer 
decision aids may help increase their efficacy even further by ensuring information is tailored 
to patients ability to understand risks and probabilities common in treatment decision.      
Over 80% of prostate cancer diagnoses in the United States are for localized prostate 
cancer (Thompson et al., 2007). As such, the majority of males diagnosed with localized 
prostate cancer fit the clinical criteria for both AS and RP. In fact, The National 




Comprehensive Cancer Network (Mohler et al., 2010) identified AS as the only treatment 
option for men with less than 20 years’ life expectancy or men with low-risk disease with less 
than 10 years’ life expectancy. With insight into the factors that affects men’s treatment 
preferences, health practitioners may be in a better position to help men make a decision that 
is more closely aligned with their values and wishes. Such knowledge will enable 
practitioners to design better decision aids and facilitate shared decision-making in the 
clinical setting.   
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AS RP Yes No 
56.22 (5.46) 80% 20% 49% 51% 2.22 (0.96) 1.37 (0.85) 2.72 (1.03) 3.41 (1.54) 3.41 (1.54) 
Note. AS: active surveillance. RP: radical prostatectomy.  
 
Table 2 
Adjusted Associations of Choosing Radical Prostatectomy Over Active 





df p Odds ratio 
Numeracy -.411 .164 6.259 1 .012 0.663 
Time discounting -.381 .185 4.226 1 .040 0.683 
Risk taking, health -.016 .038 0.169 1 .681 0.984 
Risk taking, investment -.006 .019 0.098 1 .755 0.994 
Risk taking, gambling .098 .050 3.832 1 .050 1.103 
Note. Logistic regression was used to test for adjusted associations.  The treatment outcome 




















Information presented to the participants of the study (Presentation of treatment options was 
counterbalanced). Source: http://www.cancer.gov/ 
About 17 out of every 100 men in the United States will be diagnosed with prostate 
cancer in their lifetime. However, fewer than 3 out of every 100 men in the US will die from 
prostate cancer. This is because prostate cancer often grows slowly, and men die of other causes 
such as heart disease.  
Most men with low-risk prostate cancer generally live long after their diagnosis. They 
have no or few symptoms, even without treatment. Men who have been diagnosed with low-
risk prostate cancer have a treatment choice. Active surveillance or surgery are two standard 
therapy choices for men with low-risk prostate cancer. Each has benefits (how treatments can 
help) and risks (problems treatment may cause). There is rarely just one best treatment choice.  
If a man chooses active surveillance, his doctor watches his cancer carefully. He will 
have regular check-ups that might include lab tests, ultrasounds, and biopsies. If his test results 
change, he can then choose to begin a treatment to remove or destroy his cancer. One of the 
benefits of active surveillance is the avoidance of surgery and the side effects associated with 
this surgery. However, the person may feel anxious or worried about not treating his cancer. 
There are risks involved in choosing active surveillance. With active surveillance, the cancer 
is not taken out or destroyed, so the cancer may grow and spread. If the cancer grows or spreads, 
it may no longer be curable, which can lead to death.  
Active surveillance my not be the best choice for everyone with low-risk prostate cancer. 
Some men may not want to make regular visits for testing. Others are not comfortable with the 
idea of continuing to have cancer, even if it is low-risk. Your other option is to undergo an 
immediate treatment, where you start treatment right away to try to remove your cancer.  




One possible treatment is surgery. The benefit of surgery is that the prostate cancer is 
eliminated by removing as much of the prostate as possible. The surgery, however, has short-
term and long-term side effects and drawbacks. The side effects and drawbacks include:  
1. There are risks with any major surgery, such as pain, bleeding, infection, heart problems, 
or death.  
2. After surgery, a tube will be inserted into your penis. The tube allows urine to drain 
from your bladder while the urethra is healing from the surgery. You’ll have the tube 
for 5 to 14 days.  
3. After surgery, some men may lose control of the flow of urine (urinary incontinence). 
Most men regain at least some bladder control after a few weeks. For some men, 
however, incontinence may be permanent. Studies have reported that about 14% of men 
undergoing surgery experience urinary incontinency 5 years after the surgery. 
4. Surgery may also damage nerves near the prostate and cause erectile dysfunction. 
Sexual function usually improves over several months, but for some men, this problem 
can be permanent. One study reported that about 60% of men reported some sexual 
dysfunction 18 months after the surgery. 
Recent studies show that surgery and active surveillance result in similar survival rates. 
In other words, men who choose to undergo active surveillance live as long as those who 
choose immediate treatment with surgery. Now, we would like you to imagine that YOU have 
been diagnosed with low-risk prostate cancer. Which of the two treatment options would you 
prefer? (order of answer was counterbalanced): 
1. Immediate surgery 
2. Active surveillance 
 
 
